HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO)
(“HempFusion” or the “Company”), a leading health and wellness CBD
company utilizing the power of whole-food hemp nutrition, is
pleased to announce that Mount Sinai Medical Hospital, New York
City, has selected HempFusion CBD to be used as the exclusive brand
and the sole supplier in a six-month clinical trial.
The clinical trial, comprised of two studies, is being conducted
by Dr. David Harnick, a board-certified cardiologist and
electrophysiologist and Assistant Professor in Medicine and
Cardiology at Mount Sinai, and is one of the first of its kind in
the area of CBD’s effect on targeted cardiology markers. Dr.
Harnick has constructed this long-term clinical trial to collect
data that will assist in a deeper understanding of CBD’s effect on
the body. He has chosen HempFusion for its rigors in regulatory
standards, toxicology studies for safety and quality control
adherence. The randomized, double-blinded, placebo-controlled trial
is expected to begin in March 2021.
“Studying the potential effects that CBD may have on cardiology
markers may potentially unlock some of the scientific mysteries
that exist today,” commented Dr. Harnick. “We know that there is
evidence that CBD may have beneficial effects on the body, but the
exact scope of those effects remains to be determined. There have
been no published randomized prospective controlled trials
evaluating the effects of CBD on these cardiac markers, so this
research may prove to be groundbreaking,” continued Dr.
Harnick.
“This is the second clinical trial HempFusion is proudly
participating in,” commented Jason Mitchell, N.D., HempFusion’s
co-founder and Chief Executive Officer. “We are committed to
furthering research in the area of hemp-derived CBD and this study
at Mount Sinai Hospital in New York City is a significant expansion
of our efforts that reinforces our continued focus on the safe and
effective use of hemp-derived CBD products,” continued Dr.
Mitchell.
Additionally, HempFusion is pleased to report its CBD products
are also part of the groundbreaking ValidCare Human Observational
liver and male reproductive toxicology studies, exploring the
effect of CBD on liver enzymes. In response to the FDA’s request
for science-based data to help determine the regulatory pathways
for hemp-derived CBD products, this industry-wide study measures
CBD’s effects on the liver among healthy adults, with results
expected in the coming weeks from the 1-year of planning and
execution related to what many are considering the largest Human
Observational liver and male reproductive toxicology studies done
to date.
The CBD used in these studies is the same hemp derived CBD
available to the public.
HempFusion features the use of panoramic, DNA verified
industrial hemp that delivers not only CBD, but a wide array of
cannabinoids in the ratio that is closer to that found in nature’s
true superfood: hemp. This proprietary EU commission registered,
DNA verified, hemp extract is unique in the market because it
contains a wider array of the compounds found in the hemp
plant—compounds that many other companies remove during processing.
HempFusion uses a slower, lower-heat version of CO2 extraction that
delivers the same amount of CBD per serving but may have much more
of the beneficial compounds critical to the entourage effect, such
as cannabinoids and cannaflavins. HempFusion panoramic CBD is
available in a range of products including capsules, oils and
topicals and in formulas that target sleep, energy and stress.
Learn more about them here.
ABOUT HEMPFUSION
HempFusion is a leading health and wellness CBD company
utilizing the power of whole-food hemp nutrition. HempFusion
distributes its family of brands, including HempFusion, Probulin
Probiotics, Biome Research, and HF Labs, to approximately 4,000
retail locations across all 50 states of the United States and
select international locations. Built on a foundation of regulatory
compliance and human safety, HempFusion’s diverse product portfolio
comprises 48 SKUs including tinctures, proprietary FDA Drug Listed
Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and
more. With a strong focus on research and development, HempFusion
has an additional 30 products under development. HempFusion is a
board member of the US Hemp Roundtable, and HempFusion’s
wholly-owned subsidiary, Probulin Probiotics, is one of the
fastest-growing probiotics companies in the United States,
according to SPINs reported data. HempFusion’s CBD products are
based on a proprietary Whole Food Hemp Complex™ and are available
in-store or by visiting HempFusion online at www.hempfusion.com or
www.probulin.com.
Follow HempFusion on Twitter, Facebook and Instagram and
Probulin on Twitter, Facebook and Instagram.
FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements and
forward-looking information within the meaning of Canadian
securities legislation (collectively, “forward-looking
statements“) that relate to HempFusion’s current expectations
and views of future events. Any statements that express, or involve
discussions as to, expectations, beliefs, plans, objectives,
assumptions or future events or performance (often, but not always,
through the use of words or phrases such as “will likely result”,
“are expected to”, “expects”, “will continue”, “is anticipated”,
“anticipates”, “believes”, “estimated”, “intends”, “plans”,
“forecast”, “projection”, “strategy”, “objective” and “outlook”)
are not historical facts and may be forward-looking statements and
may involve estimates, assumptions and uncertainties which could
cause actual results or outcomes to differ materially from those
expressed in such forward-looking statements. No assurance can be
given that these expectations will prove to be correct and such
forward-looking statements included in this news release should not
be unduly relied upon. These statements speak only as of the date
of this news release. In particular and without limitation, this
news release contains forward-looking statements relating to the
commencement of the clinical trial at Mount Sinai Medical Hospital,
the expected timing of the results of the ValidCare trial, the
Company’s efforts to further research in the area of hemp-derived
CBD and the Company’s other plans, focus and objectives.
Forward-looking statements are based on a number of assumptions
and are subject to a number of risks and uncertainties, many of
which are beyond HempFusion’s control, which could cause actual
results and events to differ materially from those that are
disclosed in or implied by such forward-looking statements. Such
risks and uncertainties include, but are not limited to, the impact
and progression of the COVID-19 pandemic and other factors set
forth under “Forward-Looking Statements” and “Risk Factors” in the
final long form prospectus of the Company dated December 17, 2020
and available under the Company’s profile on SEDAR at
www.sedar.com. HempFusion undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
by law. New factors emerge from time to time, and it is not
possible for HempFusion to predict all of them or assess the impact
of each such factor or the extent to which any factor, or
combination of factors, may cause results to differ materially from
those contained in any forward-looking statement. Any
forward-looking statements contained in this news release are
expressly qualified in their entirety by this cautionary
statement.
Neither the TSX nor its Regulation Services Provider (as that
term is defined in the policies of the TSX) accepts responsibility
for the adequacy or accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210217005326/en/
Jason Mitchell, N.D. Chief Executive Officer and Director Email:
ir@hempfusion.com Phone: 416-803-5638
HempFusion Wellness (TSX:CBD.U)
Historical Stock Chart
From Feb 2024 to Mar 2024
HempFusion Wellness (TSX:CBD.U)
Historical Stock Chart
From Mar 2023 to Mar 2024